- Home
- OKYO vs OCX Comparison
OKYO vs OCX Comparison
Compare OKYO & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- OCX
- Stock Information
- Founded
- OKYO 2007
- OCX 2009
- Country
- OKYO United Kingdom
- OCX United States
- Employees
- OKYO N/A
- OCX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OKYO Health Care
- OCX Health Care
- Exchange
- OKYO Nasdaq
- OCX Nasdaq
- Market Cap
- OKYO 34.5M
- OCX 38.7M
- IPO Year
- OKYO 2022
- OCX N/A
- Fundamental
- Price
- OKYO $1.03
- OCX $3.12
- Analyst Decision
- OKYO Strong Buy
- OCX Buy
- Analyst Count
- OKYO 1
- OCX 4
- Target Price
- OKYO $7.00
- OCX $4.06
- AVG Volume (30 Days)
- OKYO 13.7K
- OCX 31.9K
- Earning Date
- OKYO 10-25-2024
- OCX 11-07-2024
- Dividend Yield
- OKYO N/A
- OCX N/A
- EPS Growth
- OKYO N/A
- OCX N/A
- EPS
- OKYO N/A
- OCX N/A
- Revenue
- OKYO N/A
- OCX $1,022,999.00
- Revenue This Year
- OKYO N/A
- OCX N/A
- Revenue Next Year
- OKYO N/A
- OCX $167.93
- P/E Ratio
- OKYO N/A
- OCX N/A
- Revenue Growth
- OKYO N/A
- OCX N/A
- 52 Week Low
- OKYO $0.81
- OCX $2.08
- 52 Week High
- OKYO $2.12
- OCX $4.34
- Technical
- Relative Strength Index (RSI)
- OKYO 49.27
- OCX 53.69
- Support Level
- OKYO $0.98
- OCX $2.95
- Resistance Level
- OKYO $1.08
- OCX $3.26
- Average True Range (ATR)
- OKYO 0.05
- OCX 0.18
- MACD
- OKYO 0.00
- OCX 0.02
- Stochastic Oscillator
- OKYO 45.45
- OCX 68.54
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.